Drugs / XCEL-MC-ALPHA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02495766 | May 2015 → Nov 2017 | relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis | Blood and Tissue Bank of Catalonia | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XCEL-MC-ALPHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02495766 ↗ |
| Modality | Cell therapy | “adult autologous bone marrow mesenchymal stromal cells (BM-MSC)” NCT02495766 ↗ |
| Route | Intravenous | “single intravenous infusion of BM-MSC” NCT02495766 ↗ |